beta blockers, nebivolol (Temerit TM)
DISEASE INTERVENTION COMPARISON RESULTS
J Am Coll Cardiol. 2009 Jun 9;53(23):2150-8 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, diastolic (preserved ejection fraction), elder patients The Use of
beta blockers, nebivolol (Temerit TM)
As Treatment, Chronic
Is better Than
placebo
To reduce, at 21 months, a composite of all-cause mortality or cardiovascular hospitalizations equally in patients with preserved EF and in those with reduced EF.
Eur Heart J. 2005 Feb;26(3):215-25 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, diastolic (preserved ejection fraction), systolic, elder patients The Use of
beta blockers, nebivolol (Temerit TM)
As Treatment, Chronic
Is better Than
placebo
To reduce, at 21 months, a composite of death from all causes and cardiovascular hospital admission: 31% nebivolol VS 35% placebo. There were a non-significant reduction of death: 16% nebivolol VS 18% placebo.